|
May 09, 2008
FDC's Timolol Maleate receives a nod from the U.S. FDA FDC Limited, leaders in the field of ophthalmology, soars high with the nod it received from the U.S. FDA for its Abbreviated New Drug Application (ANDA), Timolol Maleate Ophthalmic Solution. Timolol Maleate is a nonselective beta-blocking drug, used as a primary line of treatment for glaucoma.
The Company's other two ANDAs Ciprofloxacin Ophthalmic Solution and Ofloxacin Ophthalmic Solution are in the pipeline, in the final stages of approval. Besides these three ANDAs, FDC also has on its anvil around five more products at an advanced stage of filing.
FDC has also to its credit twelve DMF's (Drug Master Files) and ten Marketing Authorizations in UK . |
